Aduro Biotech Highlights Positive Clinical Results from Second Cohort of Phase 1b Mesothelioma Clinical Trial
Data Presented at the
Continues to Show Clinical Activity of CRS-207
Two Additional Poster Presentations Detailing Promising Preclinical Results of STING and pLADD Programs
Preliminary results as of
Of note, analysis of paired tumor biopsies obtained from two patients showed a marked infiltration of immune effector cells into the tumor microenvironment (TME) following two doses of Cy/CRS-207, as compared to baseline. Post-therapeutic changes included an increase in CD8+ cytotoxic T cells as well as an increase in other immune cell types that are thought to be essential for effective immunotherapy, including dendritic cells and natural killer cells. Together, these data suggest that the Cy/CRS-207 remodeling of the TME may be an important component of the clinical responses observed in this cohort of patients.
“The data from the second cohort, which is a patient population with more advanced disease compared to the first cohort, demonstrate that the addition of immunomodulatory doses of cyclophosphamide, which has been shown to inhibit negative regulatory T cell populations, to the combination of CRS-207 and chemotherapy results in encouraging disease control and tolerability for patients with mesothelioma,” said
Additional Data on STING, pLADD Platform Technologies
A poster presentation highlighting preclinical data on the potential mechanism of action of ADU-S100 (also known as MIW315) therapy for treating cancer (Abstract #399) was given yesterday. The data showed that injection of ADU-S100 directly into the tumor microenvironment induces a systemic tumor-specific T cell response that leads to durable anti-tumor immunity. The data demonstrate that TNF-alpha and neutrophil recruitment mediate the primary tumor shrinkage following injection with ADU-S100, while CD8-alpha+ cells and natural killer cells mediate durable anti-tumor immunity. Anti-tumor efficacy was enhanced by combining ADU-S100 with anti-PD-1 or anti-CTLA4 checkpoint inhibitors. An ongoing Phase 1 clinical study is ongoing evaluating the safety and tolerability and possible anti-tumor effects of ADU-S100 in patients with cutaneously-accessible non UV-induced and UV-induced malignancies.
An additional poster presentation highlighting preclinical data on a personalized, live, attenuated double-deleted Listeria monocytogenes (pLADD) immunotherapy (Abstract #366) will be given today at
About LADD and CRS-207
LADD is Aduro's proprietary platform of live, attenuated double-deleted Listeria monocytogenes strains that have been engineered to generate a potent innate immune response and to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity.
CRS-207 is one of a family of product candidates based on Aduro's LADD immunotherapy platform that has been engineered to express the tumor-associated antigen mesothelin, which is over-expressed in many cancers including mesothelioma and pancreatic, non-small cell lung, ovarian, endometrial and gastric cancers.
About STING Pathway Activator Platform
The Aduro-proprietary STING Pathway Activator product candidates, including ADU-S100 (MIW815), are synthetic small molecule immune modulators that are designed to target and activate human STING. STING is generally expressed at high levels in immune cells, including dendritic cells. Once activated, the STING receptor initiates a profound innate immune response through multiple pathways, inducing the expression of a broad profile of cytokines, including interferons and chemokines. This subsequently leads to the development of a systemic tumor antigen-specific T cell adaptive immune response.
Aduro’s pLADD platform is a highly-personalized immunotherapy based on the live, attenuated double-deleted Listeria monocytogenes (LADD) platform. The pLADD approach leverages the immune activating activity of the Listeria bacterial vector in combination with patient-specific neoantigens, or an individual’s own cancer mutations, derived from a patient’s own tumor cells. Once administered, pLADD therapies are designed to mobilize the immune system through: 1.) an immediate recognition of the presence of Listeria as being foreign, and 2.) a specific and customized immune attack on cells containing the tumor neoantigens presented by pLADD. Aduro plans to initiate a Phase 1 clinical trial to evaluate the safety and immunogenicity of pLADD in patients with advanced gastrointestinal cancers in 2017.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, development plans for our product candidates and the potential for our technology platforms and for the eventual regulatory approval of our product candidates. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading “Risk Factors” contained in our quarterly report on Form 10-Q for the quarter ended September 30, 2016, which is on file with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Sylvia WheelerSVP, Corporate Affairs 510 809 9264 Media Contact: Susan Lehner510 809 2137 firstname.lastname@example.org